Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma

被引：1

作者：

Oleksowicz, L

Escott, P

Leichman, GC

Spangenthal, E

机构：

[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA

[2] SUNY Buffalo, Sch Med, Buffalo Gen Hosp, Dept Cardiol, Buffalo, NY USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 01期

关键词：

ventricular tachycardia; interleukin-2; renal cell carcinoma;

D O I：

10.1097/00000421-200002000-00009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the setting of interleukin-2 (IL-2) administration, tachycardias of ventricular origin are classified as serious, grade IV toxicities, necessitating the discontinuation of therapy. In this report, we describe a patient with renal cell carcinoma who experienced ventricular tachycardia while undergoing treatment with high-dose bolus IL-2. Prophylaxis with sotalol permitted the successful completion of his first cycle of treatment, without any recurrent rhythm disturbances.

引用

页码：34 / 36

页数：3

共 21 条

[1]

ARKINS MB, 1997, P AN M AM SOC CLIN, V16, P494

[2] RANDOMIZED PHASE-II TRIAL OF HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON-ALFA-2B IN ADVANCED RENAL-CELL CARCINOMA [J].

ATKINS, MB ;

SPARANO, J ;

FISHER, RI ;

WEISS, GR ;

MARGOLIN, KA ;

FINK, KI ;

RUBINSTEIN, L ;

LOUIE, A ;

MIER, JW ;

GUCALP, R ;

SOSMAN, JA ;

BOLDT, DH ;

DOROSHOW, JH ;

ARONSON, FR ;

SZNOL, M .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :661-670

[3]

BRADLEY EC, 1989, P AN M AM SOC CLIN, V8, P133

[4] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].

FYFE, G ;

FISHER, RI ;

ROSENBERG, SA ;

SZNOL, M ;

PARKINSON, DR ;

LOUIE, AC .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696

[5] Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy [J].

Fyfe, GA ;

Fisher, RI ;

Rosenberg, SA ;

Sznol, M ;

Parkinson, DR ;

Louie, AC .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2410-2411

[6] THE HEMODYNAMIC-EFFECTS OF TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS [J].

GAYNOR, ER ;

VITEK, L ;

STICKLIN, L ;

CREEKMORE, SP ;

FERRARO, ME ;

THOMAS, JX ;

FISHER, SG ;

FISHER, RI .

ANNALS OF INTERNAL MEDICINE, 1988, 109 (12) :953-958

[7]

HOHNLOSER SH, 1994, NEW ENGL J MED, V331, P31

[8]

LEE RE, 1989, J CLIN ONCOL, P7

[9] INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELL THERAPY OF SOLID TUMORS - ANALYSIS OF TOXICITY AND MANAGEMENT GUIDELINES [J].

MARGOLIN, KA ;

RAYNER, AA ;

HAWKINS, MJ ;

ATKINS, MB ;

DUTCHER, JP ;

FISHER, RI ;

WEISS, GR ;

DOROSHOW, JH ;

JAFFE, HS ;

ROPER, M ;

PARKINSON, DR ;

WIERNIK, PH ;

CREEKMORE, SP ;

BOLDT, DH .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) :486-498

[10] TOXICITY OF IMMUNOTHERAPY WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS [J].

MIER, JW ;

ARONSON, FR ;

NUMEROF, RP ;

VACHINO, G ;

ATKINS, MB .

PATHOLOGY AND IMMUNOPATHOLOGY RESEARCH, 1988, 7 (06) :459-476

← 1 2 3 →